Dual contraceptive utilization and associated factors Among hiv positive women attending art clinic in nigist Ellen mohammed memorial hospital, hosanna, Ethiopia

Abstract

Background: Human immune deficiency virus continues to have disastrous medical, economic, social, and physical impacts on individuals, their communities and the nations of the world. Sub-Saharan Africa is at the epicenter of the epidemic and continues to carry the full brunt of its health and socioeconomic impact. Dual protection is a strategy that prevents both unwanted pregnancy and sexually transmitted infections, including human immune deficiency virus. Also antiretroviral treatment has contributed a lot in decline of human immune deficiency virus related morbidity and mortality. Objectives: To assess dual contraceptive utilization and associated factors among women living with human immune deficiency virus in Nigist Ellen Mohammed Memorial Hospital, Hossana, South Nation Nationalities and Peoples Regional State, Ethiopia. Methods: Facility based cross-sectional study was conducted among women living with human immune deficiency virus in Nigist Ellen Mohammed Memorial Hospital. Data were collected through face-to-face interview using structured questionnaires. Participants were selected by using simple random sampling technique from sampling frame. Descriptive statistics was done to describe the data. Bivariate and multivariable analysis was performed using logistic regression on SPSS version 20.0 software/ Adjusted odds ratio along with 95%CI were estimated to identify factors associated with dual contraceptive utilization. Level of statistical significance was decleared at p-value less than 0.05. Results: The prevalence of dual contraceptive utilization of women living with human immune deficiency virus in Nigist Ellen Mohammed Memorial Hospital was 28.3% (95% CI: 23.8, 33.7). Dual contraceptive utilization was significantly associated with participants who receiving follow up counseling in the last three months (AOR: 6.05; 95% CI: 2.46, 14.83), starting antiretroviral treatment (AOR: 0.21; CI: 0.07, 0.64), had no child (AOR: 0.19; 95% CI: 0.06, 0.57), supporting to use dual contraceptive utilization (AOR: 6.36; 95% CI: 2.49, 16.28). Conclusions: Dual contraception utilization by women living with human immune deficiency virus was low and had no child; receiving follow up counseling in the last 3 months; starting antiretroviral treatment; supporting to use dual contraceptive methods were associated with dual contraceptive utilization